https://doi.org/10.17795/ijpbs340

A Fresh Look at the Potential Mechanisms of Progressive Muscle Relaxation Therapy on Depression in Female Patients With Multiple Sclerosis

authors:

avatar Seyyedeh Zahra Safi 1 , *

Department of Psychology Science, Payame Noor University, Tehran, IR Iran
Iranian Journal of Psychiatry and Behavioral Sciences: Vol.9, issue 1
published online: March 21, 2015
article type: Original Article
received: July 16, 2014
revised: November 28, 2014
accepted: January 21, 2015

How To Cite Safi S Z. A Fresh Look at the Potential Mechanisms of Progressive Muscle Relaxation Therapy on Depression in Female Patients With Multiple Sclerosis. Iran J Psychiatry Behav Sci. 2015;9(1): -. https://doi.org/10.17795/ijpbs340.

Abstract

Background:

According to the World Health Organization (WHO) report released in 2000, about 121 million people worldwide suffer from depression. The major depressive disorder (MDD) among multiple sclerosis (MS) patients is one of the most common mood disorders experienced during life. MS patients who simultaneously suffer from depression have reported more severe symptoms of disease and slower adaptation to new conditions, which ultimately increase the cost of treatment.

Objectives:

The aim of this study was to assess the effectiveness of progressive muscle relaxation therapy (PMRT) as an adjunctive therapy for reducing level of depression for MS patients.

Materials and Methods:

This research had the randomized controlled trial design with pre and posttest. Thirty female patients based on criteria of MS and MDD disease, were selected from the MS Society of Shiraz, Iran. Beck Depression Inventory (BDI-II) was administered at pre and posttest. The participants were randomly allocated to two groups (experimental and control). Twelve sessions of PMRT using Bernstein and Borkovec’s method were held for the experimental group. Levin’s test, covariance and ANOVA with repeated measures were used for data analysis.

Results:

Experimental and control groups were compared before and after treatment. Analysis of covariance showed that seven levels of depression decreased in the experimental group and analysis of repeated measure showed that 49% of the changes were related to PMRT.

Conclusion:

According to the results, PMRT is effective in reducing depression. This therapy enables patients to reach relaxation quickly, and thus can cope with depression reactions effectively.

1. Background

Multiple sclerosis (MS) is a disease with a variable course. This disease usually occurs with reversible periods of neurological disability during the third and fourth decades of life and finally, in the sixth or seventh decades of life, this disease becomes an irreversible neurological disorder and permanent disability (1). MS disease is demarcated with inflammation and destruction of white matter of the brain and spinal cord and its replacement with gliotic tissue (2). The etiology of disease this unknown, however, strong evidence for irreversible neurological disability in MS patients indicates that MS disease is an autoimmune disease against central nervous system myelin or neuron degeneration (3).

MS disease has been reported 1.8 times more in females than males and has a profound effect on the personal lives of individuals (4). One million people in the world suffer from MS that is comorbid with psychiatric disorders (5). Cognitive impairment is common in this disease (6). Prevalence of cognitive impairment is about 30.5%, and affects attention, concentration, performance, processing speed and visual perception. Non-somatic symptoms of depression, can predict cognitive performance but it is not clear how depression affects cognitive impairment (7).

On the other hand somatic and non-somatic symptoms of depression predict exacerbation of MS disease (8). Therefore, interaction between medical and psychological variables in MS disease is complex. MS disease usually indicates disparate disease periods (4). The cause and cure are unknown; appearance, removal and even relapsing of symptoms occurs without any warning signs (9) and the onset of the disease may be acute or gradual (10).

MS disease may prevent some patients from activities such as, employment, relationships (social, familial and sexual), goals and long-term plans and activities of daily life (9). Therefore these disabilities will challenge people with MS disease, when they are attempting to pursue an active and compatible lifestyle (11). It seems that unpredictable courses of disease activity influence many different fields of the patient’s life. Unpredictable periods can make severe feelings of helplessness and depression in patients with MS, while the hopelessness hypothesis states that unpredictable and negative events in the patient’s life leads to depression (12). On the other hand, depression is an important predictor of psychological balance of MS patients (13), and studies have confirmed that there are relationships between structural brain lesions and depression in MS patients (12). There is a possibility that mental health status can change period of MS disease; as Charcot (1879), has discussed, grief and worry might influence onset and exacerbation of disease symptoms. Recent research has provided some evidence regarding the relationship between emotional states and disease activity in MS disease (9).

A variety of studies have confirmed the relationship between structural brain lesions in MS patients and depression (12). Measurement of depression in patients with MS is complicated because some of the symptoms are identical between depression and MS disease (sexual dysfunction, excessive fatigue, cognitive difficulties, psychomotor retardation, mood changes, sleep changes and emotional changes) (14). Patients with MS often hide symptoms of depression and they complain from other symptoms (15). Therefore, treatment plans for depression among MS patients should be treated with an individual and integrated approach (16). Currently there are no definitive treatment for MS disease and medications only reduce relapse rate, prolong remission, limit the onset of new MS lesions, and postpone the development of long-term disability (17). Nowadays the goal of all current and emerging therapeutic strategies for these patients is to return them to a normal life despite of their disease, and several therapies (modafinil, dalfampridine, baclofen, diazepam, gabapentin and opioids) have been used for symptomatic treatment of disability and symptoms, yet they do not improve disease outcome (17).

For managing the symptoms of MS disease and improving or maintaining function and preserving the patient’s quality of life, careful clinical monitoring and pharmacologic and non-pharmacologic therapies are recommended (18). Complementary therapies (such as non-pharmacologic therapies) are widely used by MS patients, and progressive muscle relaxation therapy (PMRT) is a form of complementary therapy (19). The relaxation response is a physiological state and incompatible response against stress response (20). Muscle tension is usually associated with stress and anxiety, which are strongly related to depression. In fact, relaxation therapy is comprised of several methods that show patients how to achieve relaxation. Most programs include training special breathing and progressive muscle relaxation procedures (tension-release cycles) to reduce physical and mental tension (21).

PMRT was first identified by Jacobson in 1934 as a way for tensing and releasing 16 muscle groups. He stated that the mind and selected muscles work together in an integrated manner. Muscles and body can be relaxed or can be kept away from stress, anxiety and sympathetic activity with mental relaxation (22). Wolpe in 1948 adopted this technique for systematic desensitization therapy. Bernstein and Borkovec in 1973 adopted this technique for stress management in cognitive-behavioral therapy and they developed a shortened and modified form of the PMRT, and currently this form of relaxation therapy is being commonly used. Some of these adjustments are: seven or four muscle groups, relaxation through recall, recall and counting, and counting (22, 23).

Previous studies have indicated that depression is prevalent in MS patients and affects treatment adherence and is associated with neurological damage that results from MS (24-42). Despite the high prevalence of depression in patients with MS and its severe impact on physical and mental health, nowadays there are no completely effective treatments for depression (5). There are significant results indicating the effectiveness of PMRT on the normal human brain and patients with MS and a brain lesion that suffer from depression; for example an investigation of 13 controlled studies on patients without brain lesions revealed that PMRT for depression treatment in different patients (such as, multiple somatoform syndrome, cancer disease, pulmonary disease, cardiac disease, muscular pain, tinnitus disease and night eating syndrome) is better than no treatment, placebo treatment, or other behavioral methods. Also follow-up (after several months) treatments were more effective than the first intervention (43-55). A few studies, have shown that PMRT is effective on quality of life, wellbeing and stress management, and this reduces symptoms such as pain, fatigue, anxiety and depression (9, 55-57).

2. Objectives

The aim of this study was to determine whether PMRT could reduce the level of major depressive disorder in female MS patients of the Shiraz Multiple Sclerosis Aid Society.

3. Materials and Methods

This study was an applied-experimental research with randomized controlled trial design plus pre and posttests. This study compared two groups; experimental and control, where the first group received PMRT and the second group did not receive any treatment for depression, respectively.

In spring 2010, from the 2800 MS patients of the Shiraz Multiple Sclerosis Aid Society (SHMSAS), 30 depressed female volunteers participated in relaxation therapy. They answered the questionnaire before the intervention. Criteria of MS and major depressive disorder (MDD) disease from minimal to severe were confirmed by the SHMSAS and BDI-II, and after the pretest they were randomly divided to two groups. The experimental group received standard care for MS disease plus 60 minutes of psychological intervention (PMRT) for each session (twice a week for six weeks) while the control group received only standard care for MS disease, and at completion the two groups cooperated again in the posttest.

Ethical considerations and rights were applied for this research (respect of the basic rights of patients such as, privacy, cultural and social values, freedom of choice and honesty about characteristics of therapy and therapist’s competence). The cases of the two groups were matched in terms of age, marital status, education and income. Selection criteria for inclusion and exclusion were as follows:

1- Agreement of the individual to participate in the research, 2- at least literacy for reading and writing, 3- physical ability to participate in therapy sessions, 4- doing homework daily at home, 5- filling notes every week, 6- not having any psychotic disorder, bipolar disorder (depressive episode) and major depressive disorder with psychotic features.

There was no drop out of patients during the intervention, and after treatment, patients of both groups answered the questionnaire for the second time.

3.1. Tools

In this study progressive muscle relaxation, method of Bernstein et al. (22), and also the Beck Depression Questionnaire (Beck, Epstein, Brown and Steer, 1988) were used, with the reliability and validity examined for the Iranian population (the validity of questionnaire was confirmed by the positive correlation between BDI-II and brief symptom inventory (BSI)); Pearson’s coefficient was 0.87, and factor analysis (to determine underlying relationships between variables) showed three factors: physical, cognitive and affective. The reliability of the questionnaire using the method of internal consistency was 0.91 (Cronbach’s alpha coefficient) (58).

The BDI-II was developed based on the criteria of diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV) for diagnosing depressive disorders (59). The BDI-II is a brief scale that is acceptable for researchers in clinical observations and patient description. As a screening instrument, validity and capability of case-finding for this questionnaire has been proved. It is a subjective paper and pencil questionnaire with ordinal scale for depression as a qualitative variable. In addition cut-off points 0-13, 14-19, 20-28 and 29-63 indicate minimal, mild, moderate and severe depression (59).

3.2. Validity and Reliability

Content validity of the questionnaire was improved by rewording and adding items to assess DSM-IV criteria for depression. Also validity was confirmed by the positive correlation between Hamilton Depression Rating Scale, Edinburg Postnatal Depression Scale and the Hospital Anxiety, and Depression Scale-Depression, with a Pearson r of 0.62 to 0.81. The reliability of the questionnaire using retest coefficients and internal consistency was 0.93 (by Pearson’s correlation) and 0.91 (by Cronbach’s alpha coefficient) (59).

3.4. Data Analysis Method

To eliminate uncontrolled variables (the effect of pre-test on the post-test) analysis of covariance was used (analysis of covariance eliminates the covariate variable). Also Levine Test was used for revealing the difference between the two groups. The experimental design of this study included the independent (PMRT) and dependent variable (depression), while analysis of variance used the method of repeated measures.

4. Results

Thirty patients participated in this study that were randomly divided in two groups (experimental and control). Tables 1 and 2 were designed for a glimpse to background variables and descriptive statistics of depression.

Table 1.

Background Variables of the Two Groups (Experimental and Control) a

ControlExperimentalTotal
Age
Second decade4 (0.26)5 (0.33)9 (0.60)
Third decade6 (0.40)5 (0.33)11 (0.73)
Fourth decade3 (0.20)4 (0.26)7 (0.46)
Fifth decade2 (0.13)1 (0.60)3 (0.20)
Education degree
High school4 (0.26)3 (0.20)7 (0.23)
Diploma5 (0.33)4 (0.26)9 (0.30)
Bachelor6 (0.40)8 (0.53)14 (0.46)
Master0 (0.00)0 (0.00)0 (0.00)
Marital status
Single5 (0.33)7 (0.46)12 (0.40)
Married6 (0.40)5 (0.33)11 (0.36)
Divorced2 (0.13)2 (0.13)4 (0.13)
Widow2 (0.13)1 (0.60)3 (0.10)
Sick precedent
Less than 2 years4 (0.26)4 (0.26)8 (0.26)
2 to 5 Years3 (0.20)2 (0.13)5 (0.16)
5 to 10 Years8 (0.53)7 (0.46)15 (0.50)
More than ten years0 (0.00)2 (0.13)2 (0.60)

a Data are presented as No. (%).

Table 2.

Descriptive Statistics of Depression Variables

ControlExperimentalTotal
BeforeAfterBeforeAfterBeforeAfter
Mean15.8615.9316.208.4016.0312.16
Median13131651410
Mode1110115115
Sum238239243126481365
Standard deviation9.769.729.509.439.4610.16
Variance95.2694.4990.3188.989.62103.24
Range313136403740
Maximum343440404040

Table 1 reveals that most patients in this study were in their third decade of life and most of them had a bachelor’s degree of education and single patients were more than others while half of them were sick for more than five years and they had experienced symptoms from mild to severe. Table 2 shows that all patients had depression and some of them had severe depression and in the experimental group the mean value indicates mild depression. The research hypothesis stated that, PMRT reduces depression level in MS patients and this hypothesis was checked by Tables 3,4 and 5.

Table 3.

Levine Test Results About Equal Variances in the Two Groups

DepressionFFirst-Degree of FreedomSecond-Degree of FreedomSignificance Level
0.4631280.502
Table 4.

The Estimate of Average Depression Variable

Experimental GroupAverage aNumberMeaningful Level
Before intervention16.08 ± 1.03150.000
After intervention8.24 ± 1.03150.000

a Data are presented as Mean ± SD.

Table 5.

Results of Variance Analysis with Repeated Measures Method

Source of ChangesTotal SquareMean SquareFSignificanceEffectStatistical Power
Depression224.26224.2627.460.00010.4999
Interaction depression and group232.06232.0628.410.00010.5599
Error228.668.16

Table 3, was designed to measure the equality of variances between groups. The results indicate that there was no significant difference in the variance of groups. The purpose of covariance analysis in Table 4 was to eliminate the covariate variable from the dependent variable and to estimate the central indexes. The results showed the mean and standard deviation had increased, by eliminating the impact of pre-test on the post-test and with considering the significance level. After the treatment of the experimental group, a significant reduction in depression variable occurred in seven levels. In Table 5, the impact of the independent variable on depression level was reviewed by analysis of variance with the repeated measures method.

Table 5 showed that the difference between pre-test and post-test was significant (P = 0.0001), indicating a 49% reduction in depression levels, which means that this reduction had occurred because of the relaxation therapy, with statistical power of 99%. The results of interaction depression and group showed significant increase effect in interaction weeks of treatment and group membership.

Acknowledgements

References

  • 1.

    Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-69. [PubMed ID: 18558855].

  • 2.

    Masoud SA, Fakharian E. Assessment of serum magnesium, copper, and zinc levels in multiple sclerosis (MS) patients. IJPBS. 2007;1(2):38-42.

  • 3.

    Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med. 2002;53:285-302. [PubMed ID: 11818475]. https://doi.org/10.1146/annurev.med.53.082901.103909.

  • 4.

    Shnek ZM, Foley FW, LaRocca NG, Gordon WA, DeLuca J, Schwartzman HG, et al. Helplessness, self-efficacy, cognitive distortions, and depression in multiple sclerosis and spinal cord injury. Annals of Behavioral Medicine. 1997;19(3):287-94.

  • 5.

    Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. Int Scholar Res Notice. 2012;2012.

  • 6.

    Hardmeier M, Schoonheim MM, Geurts JJ, Hillebrand A, Polman CH, Barkhof F, et al. Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography. PLoS One. 2012;7(7). e42087. [PubMed ID: 22848712]. https://doi.org/10.1371/journal.pone.0042087.

  • 7.

    Sundgren M, Maurex L, Wahlin A, Piehl F, Brismar T. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis. Arch Clin Neuropsychol. 2013;28(2):144-55. [PubMed ID: 23291310]. https://doi.org/10.1093/arclin/acs113.

  • 8.

    Burns MN, Nawacki E, Siddique J, Pelletier D, Mohr DC. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013;75(1):76-82. [PubMed ID: 23197840]. https://doi.org/10.1097/PSY.0b013e3182757b2b.

  • 9.

    Sutherland G, Andersen MB, Morris T. Relaxation and health-related quality of life in multiple sclerosis: the example of autogenic training. J Behav Med. 2005;28(3):249-56. [PubMed ID: 16015459]. https://doi.org/10.1007/s10865-005-4661-2.

  • 10.

    McCabe MP, McKern S. Quality of life and multiple sclerosis: Comparison between people with multiple sclerosis and people from the general population. J Clin Psychol Med Set. 2002;9(4):287-95.

  • 11.

    White LJ, Dressendorfer RH. Exercise and multiple sclerosis. Sport Med. 2004;34(15):1077-100.

  • 12.

    Kneebone ,I, Dunmore E. Attributional style and symptoms of depression in persons with multiple sclerosis. Int J Behav Med. 2004;11(2):110-5. [PubMed ID: 15456680].

  • 13.

    Chen K, Fan Y, Hu R, Yang T, Li K. Impact of depression, fatigue and disability on quality of life in Chinese patients with multiple sclerosis. Stress Health. 2013;29(2):108-12. [PubMed ID: 22566371]. https://doi.org/10.1002/smi.2432.

  • 14.

    Moran PJ, Mohr DC. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med. 2005;28(1):35-41. [PubMed ID: 15887874].

  • 15.

    Alschuler KN, Ehde DM, Jensen MP. The co-occurrence of pain and depression in adults with multiple sclerosis. Rehabil Psychol. 2013;58(2):217-21. [PubMed ID: 23713732]. https://doi.org/10.1037/a0032008.

  • 16.

    Schumann R, Adamaszek M, Sommer N, Kirkby KC. Stress, depression and antidepressant treatment options in patients suffering from multiple sclerosis. Curr Pharm Des. 2012;18(36):5837-45. [PubMed ID: 22681164].

  • 17.

    Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care. 2013;19(2 Suppl):S21-7. [PubMed ID: 23544717].

  • 18.

    Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther. 2006;28(4):445-60. [PubMed ID: 16750459]. https://doi.org/10.1016/j.clinthera.2006.04.005.

  • 19.

    Ghafari S, Ahmadi F, Nabavi M, Anoshirvan K, Memarian R, Rafatbakhsh M. Effectiveness of applying progressive muscle relaxation technique on quality of life of patients with multiple sclerosis. J Clin Nurs. 2009;18(15):2171-9. [PubMed ID: 19583649].

  • 20.

    Chang BH, Dusek JA, Benson H. Psychobiological changes from relaxation response elicitation: long-term practitioners vs. novices. Psychosomatics. 2011;52(6):550-9. [PubMed ID: 22054625]. https://doi.org/10.1016/j.psym.2011.05.001.

  • 21.

    Jorm AF, Morgan AJ, Hetrick SE. Relaxation for depression. J Cochrane Database Syst Rev. 2008;8(4).

  • 22.

    Bernstein D, Borkovec T, Carlson K. Progressive relaxation training: a manual for the helping profession. Mashhad: Ferdowsi University Press; 1992.

  • 23.

    McCallie MS, Blum CM, Hood CJ. Progressive muscle relaxation. J Human Behav Social Environ. 2006;13(3):51-66.

  • 24.

    Firth N. Effectiveness of psychologically focused group interventions for multiple sclerosis: A review of the experimental literature. J Health Psychol. 2013;19(6):789-801. [PubMed ID: 23520348]. https://doi.org/10.1177/1359105313479630.

  • 25.

    Stepleman LM, Decker M, Rollock M, Casillas R, Brands T. Depression screening in Black Americans with multiple sclerosis. Psychol Health Med. 2014;19(1):33-9. [PubMed ID: 23514346]. https://doi.org/10.1080/13548506.2013.775466.

  • 26.

    Kisic Tepavcevic D, Pekmezovic T, Stojsavljevic N, Kostic J, Dujmovic Basuroski I, Mesaros S, et al. Predictive value of health-related quality of life in progression of disability and depression in persons with multiple sclerosis: a 3-year study. Acta Neurol Belg. 2013;113(4):403-9. [PubMed ID: 23460394]. https://doi.org/10.1007/s13760-013-0191-9.

  • 27.

    Nielsen-Prohl J, Saliger J, Guldenberg V, Breier G, Karbe H. Stress-stimulated volitional coping competencies and depression in multiple sclerosis. J Psychosom Res. 2013;74(3):221-6. [PubMed ID: 23438712]. https://doi.org/10.1016/j.jpsychores.2012.11.003.

  • 28.

    O Donnchadha S, Burke T, Bramham J, O'Brien MC, Whelan R, Reilly R, et al. Symptom overlap in anxiety and multiple sclerosis. Mult Scler. 2013;19(10):1349-54. [PubMed ID: 23413298]. https://doi.org/10.1177/1352458513476742.

  • 29.

    Schroder A, Heider J, Zaby A, Gollner R. Cognitive behavioral therapy versus progressive muscle relaxation training for multiple somatoform symptoms: Results of a randomized controlled trial. Cog Thera Res. 2013;37(2):296-306.

  • 30.

    Sarisoy G, Terzi M, Gumus K, Pazvantoglu O. Psychiatric symptoms in patients with multiple sclerosis. Gen Hosp Psychiatry. 2013;35(2):134-40. [PubMed ID: 23260339].

  • 31.

    Wood B, van der Mei IA, Ponsonby AL, Pittas F, Quinn S, Dwyer T, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler. 2013;19(2):217-24. [PubMed ID: 22729988]. https://doi.org/10.1177/1352458512450351.

  • 32.

    Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, et al. A large-scale study of anxiety and depression in people with Multiple Sclerosis: a survey via the web portal of the UK MS Register. PLoS One. 2012;7(7). e41910. [PubMed ID: 22860028]. https://doi.org/10.1371/journal.pone.0041910.

  • 33.

    Ghajarzadeh M, Sahraian MA, Fateh R, Daneshmand A. Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis. Acta Med Iran. 2012;50(4):244-9. [PubMed ID: 22592574].

  • 34.

    Sjonnesen K, Berzins S, Fiest KM, M. Bulloch AG, Metz LM, Thombs BD, et al. Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. Postgrad Med. 2012;124(5):69-77. [PubMed ID: 23095427]. https://doi.org/10.3810/pgm.2012.09.2595.

  • 35.

    Pozzilli C, Schweikert B, Ecari U, Oentrich W, Bugge JP. Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. J Neurol. 2012;259(11):2319-28. [PubMed ID: 22527232]. https://doi.org/10.1007/s00415-012-6492-8.

  • 36.

    Dubayova T, Krokavcova M, Nagyova I, Rosenberger J, Gdovinova Z, Middel B, et al. Type D, anxiety and depression in association with quality of life in patients with Parkinson's disease and patients with multiple sclerosis. Qual Life Res. 2013;22(6):1353-60. [PubMed ID: 23054489]. https://doi.org/10.1007/s11136-012-0257-9.

  • 37.

    Fiest KM, Patten SB. The multiple sclerosis depression rating scale. Expert Rev Neurother. 2012;12(9):1053-5. [PubMed ID: 23039384]. https://doi.org/10.1586/ern.12.89.

  • 38.

    Labuz-Roszak B, Kubicka-Baczyk K, Pierzchala K, Machowska-Majchrzak A, Skrzypek M. Fatigue and its association with sleep disorders, depressive symptoms and anxiety in patients with multiple sclerosis. Neurol Neurochir Pol. 2012;46(4):309-17. [PubMed ID: 23023429].

  • 39.

    Moore P, Hirst C, Harding KE, Clarkson H, Pickersgill TP, Robertson NP. Multiple sclerosis relapses and depression. J Psychosom Res. 2012;73(4):272-6. [PubMed ID: 22980532]. https://doi.org/10.1016/j.jpsychores.2012.08.004.

  • 40.

    Brown RF, Valpiani EM, Tennant CC, Dunn SM, Sharrock M, Hodgkinson S, et al. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother. 2009;82(Pt 1):41-56. [PubMed ID: 18727845]. https://doi.org/10.1348/147608308X345614.

  • 41.

    Kehler MD, Hadjistavropoulos HD. Is health anxiety a significant problem for individuals with multiple sclerosis? J Behav Med. 2009;32(2):150-61. [PubMed ID: 19015971]. https://doi.org/10.1007/s10865-008-9186-z.

  • 42.

    Skerrett TN, Moss-Morris R. Fatigue and social impairment in multiple sclerosis: the role of patients' cognitive and behavioral responses to their symptoms. J Psychosom Res. 2006;61(5):587-93. [PubMed ID: 17084135]. https://doi.org/10.1016/j.jpsychores.2006.04.018.

  • 43.

    Isa MR, Moy FM, Abdul Razack AH, Zainuddin ZM, Zainal NZ. Impact of applied progressive deep muscle relaxation training on the level of depression, anxiety and stress among prostate cancer patients: a quasi-experimental study. Asian Pac J Cancer Prev. 2013;14(4):2237-42. [PubMed ID: 23725119].

  • 44.

    Cafarella PA, Effing TW, Usmani ZA, Frith PA. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology. 2012;17(4):627-38. [PubMed ID: 22309179].

  • 45.

    Vazquez FL, Torres A, Blanco V, Diaz O, Otero P, Hermida E. Comparison of relaxation training with a cognitive-behavioural intervention for indicated prevention of depression in university students: a randomized controlled trial. J Psychiatr Res. 2012;46(11):1456-63. [PubMed ID: 22939979]. https://doi.org/10.1016/j.jpsychires.2012.08.007.

  • 46.

    Hashim HA, Hanafi Ahmad Yusof H. The effects of progressive muscle relaxation and autogenic relaxation on young soccer players' mood states. Asian J Sports Med. 2011;2(2):99-105. [PubMed ID: 22375225].

  • 47.

    Chang BH, Casey A, Dusek JA, Benson H. Relaxation response and spirituality: Pathways to improve psychological outcomes in cardiac rehabilitation. J Psychosom Res. 2010;69(2):93-100. [PubMed ID: 20624507]. https://doi.org/10.1016/j.jpsychores.2010.01.007.

  • 48.

    Lolak S, Connors GL, Sheridan MJ, Wise TN. Effects of progressive muscle relaxation training on anxiety and depression in patients enrolled in an outpatient pulmonary rehabilitation program. Psychother Psychosom. 2008;77(2):119-25. [PubMed ID: 18230945]. https://doi.org/10.1159/000112889.

  • 49.

    Persson AL, Veenhuizen H, Zachrison L, Gard G. Relaxation as treatment for chronic musculoskeletal pain–a systematic review of randomised controlled studies. Phys Ther Rev. 2008;13(5):355-65.

  • 50.

    Pawlow LA, O'Neil PM, Malcolm RJ. Night eating syndrome: effects of brief relaxation training on stress, mood, hunger, and eating patterns. Int J Obes Relat Metab Disord. 2003;27(8):970-8. [PubMed ID: 12861239]. https://doi.org/10.1038/sj.ijo.0802320.

  • 51.

    McGrady AV, Kern-Buell C, Bush E, Devonshire R, Claggett AL, Grubb BP. Biofeedback-assisted relaxation therapy in neurocardiogenic syncope: a pilot study. Appl Psychophysiol Biofeedback. 2003;28(3):183-92. [PubMed ID: 12964450].

  • 52.

    Sloman R. Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. Cancer Nurs. 2002;25(6):432-5. [PubMed ID: 12464834].

  • 53.

    Weber C, Arck P, Mazurek B, Klapp BF. Impact of a relaxation training on psychometric and immunologic parameters in tinnitus sufferers. J Psychosom Res. 2002;52(1):29-33. [PubMed ID: 11801262].

  • 54.

    Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psychooncology. 2001;10(6):490-502. [PubMed ID: 11747061].

  • 55.

    Artemiadis AK, Vervainioti AA, Alexopoulos EC, Rombos A, Anagnostouli MC, Darviri C. Stress management and multiple sclerosis: a randomized controlled trial. Arch Clin Neuropsychol. 2012;27(4):406-16. [PubMed ID: 22491729]. https://doi.org/10.1093/arclin/acs039.

  • 56.

    Molina-Rueda F, Perez de la C. Multiple sclerosis and relaxation techniques. J Revista Iberoamericana Kinesiology and Physiotherapy. 2009;12(1):28-34.

  • 57.

    Ghafari S, Ahmadi F, Nabavi M, Memarian R. Effects of applying progressive muscle relaxation technique on depression, anxiety and stress of multiple sclerosis patients in Iran National MS Society. Pejouhesh. 2008;32(1):45-53.

  • 58.

    Dabson KE, Mohamadkhani P. Psychometric characteristics of BDI-II in patients of MDD. J Rehab. 2007;8(29):104-11.

  • 59.

    Wang YP, Gorenstein C. Assessment of depression in medical patients: a systematic review of the utility of the Beck Depression Inventory-II. Clinics (Sao Paulo). 2013;68(9):1274-87. [PubMed ID: 24141845].

  • 60.

    Wilson P. Immediate Relief. Tehran: Peykan Press; 2000.

  • 61.

    Sadok VA, Kaplan H. Kaplan and Sadock' synopsis of psychiatry: behavioral sciences - clinical psychiatry. Tehran: Shahre Abe Press; 2003.